Let's break down Fortis Healthcare (India) Ltd. (FORTIS) — from its financial performance to how the market is valuing the stock.
Fortis Revenue Trend
At ₹7,850 Cr, Fortis Healthcare (India) Ltd.'s FY2025 revenue was 13.3% ahead of the ₹6,931 Cr posted in FY2024.
The 10-year revenue CAGR of 7.1% reflects steady — if not spectacular — top-line expansion from ₹3,966 Cr to ₹7,850 Cr.
At ₹7,850 Cr in annual revenue, Fortis Healthcare (India) Ltd. is one of the mid-sized players in the healthcare space.
The consistency stands out: 4 consecutive years of growth in top-line revenue.
| Year | Revenue | YoY % |
|---|---|---|
| FY2025 | ₹7,850 Cr | +13.3% |
| FY2024 | ₹6,931 Cr | +9.0% |
| FY2023 | ₹6,359 Cr | +10.7% |
| FY2022 | ₹5,745 Cr | +42.6% |
| FY2021 | ₹4,030 Cr | — |
View Fortis Healthcare (India) Ltd.'s full 10-year revenue trend with CAGR analysis →
Fortis Profitability
On the profitability front, Fortis Healthcare (India) Ltd. did well — net income rose 25.4% to ₹809 Cr from ₹645 Cr a year earlier.
The company squeezed out better margins in FY2025, with net margin at 10.3% versus 9.3% in FY2024.
Looking at per-share numbers, diluted EPS was ₹10.26 in FY2025 — up from ₹7.93.
Is Fortis Undervalued
The P/E Ratio model estimates an intrinsic value of ₹602, implying a 35.3% downside from the current price.
Fortis Healthcare (India) Ltd. shares are currently trading at ₹930.25.
Craytheon also calculates intrinsic value using the EPS Growth and DCF models. The full breakdown with assumptions is available in the detailed analysis.
| Model | Est. Fair Value | vs. Current Price |
|---|---|---|
| P/E Ratio | ₹602 | 35.3% downside to fair value |
| EPS Growth | Upgrade | Upgrade |
| DCF | Upgrade | Upgrade |
See all valuation models for Fortis Healthcare (India) Ltd. with detailed assumptions →
Fortis Shareholding Pattern
Promoters continue to hold 31.2% of the company, unchanged over recent quarters.
FII holding stands at 26.0%, down from 27.2% in the year-ago quarter.
Domestic institutional investors (DIIs) held 31.4% as of March 2026, up from 29.8% a year ago.
| Quarter | Promoter | FII | DII | Public |
|---|---|---|---|---|
| Mar 2026 | 31.2% | 26.0% | 31.4% | 11.5% |
| Dec 2025 | 31.2% | 27.8% | 29.3% | 11.7% |
| Sep 2025 | 31.2% | 27.9% | 29.1% | 11.8% |
| Jun 2025 | 31.2% | 27.2% | 29.8% | 11.9% |
Track quarterly shareholding changes for Fortis Healthcare (India) Ltd. →
Fortis Balance Sheet
Proportional view as of 3 Jun 2026. Hover blocks for details.
Assets
Liabilities & Equity
FY2025 total assets: ₹136.92B (up 3.0% YoY from ₹132.89B).
Top categories: Property, Plant & Equipment (37.3%), Intangibles & Goodwill (33.4%), Other Assets (17.8%).
Of the ₹136.92B in liabilities and equity, 67.0% is shareholder equity, 18.1% is interest-bearing debt, and 15.0% is operating liabilities. Over the year, debt is up 114.3% and equity is up 7.2%.
Balance sheet composition — FY 2025
| Category | Value |
|---|---|
| Cash & ST Investments | 5.08B |
| Receivables | 7.84B |
| Inventories | 1.15B |
| Property, Plant & Equipment | 51.01B |
| Investments | 1.69B |
| Intangibles & Goodwill | 45.78B |
| Other Assets | 24.36B |
| Category | Value |
|---|---|
| Equity | 91.69B |
| Short-term Debt | 1.64B |
| Long-term Debt | 23.11B |
| Trade Payables | 8.08B |
| Other Liabilities | 12.39B |
Fortis Key Highlights
Here's the bottom line on Fortis Healthcare (India) Ltd. (FORTIS) based on the latest available financials.
Revenue of ₹7,850 Cr in FY2025, up 13.3% year-over-year.
Long-term revenue has been compounding at 7.1% annually over 10 years.
The company is profitable, with a net margin of 10.3% and net income of ₹809 Cr.
The P/E Ratio model implies 35.3% downside to fair value from the current price. The remaining two models are worth cross-checking before drawing a conclusion — sign up to see the full analysis.
Unlock Full Analysis
For the complete 10-year financial history with interactive charts and growth analysis, explore Fortis Healthcare (India) Ltd.'s detailed profile on Craytheon.